Clinical Trial Search

Phase 3 N=1,405 A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

Type 1 Diabetes Mellitus (T1DM) · High Level of Sugar (Glucose) in the Blood

Primary: Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization — 15.2; 28.6…

Lexicon Pharmaceuticals Results Nov 2019 5.1% serious AE View details

Phase 3 N=61 Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

Major Depressive Disorder · Overweight · Inflammation

Primary: Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL) — 1.92; -1.27; 7.19; 4.45 percentage of change in plasma levels…

Massachusetts General Hospital Results Nov 2019 0.0% serious AE View details

Phase 3 N=394 A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

Primary: Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA]) — NA; 22.29 Weeks — p=<0.001

Eli Lilly and Company Results Nov 2019 3.0% serious AE View details

Phase 3 N=50 Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

Acne Vulgaris

Primary: Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire — 36 Participants

Galderma R&D Results Nov 2019 0.0% serious AE View details

Phase 3 N=329 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Influenza A · Influenza B

Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33

National Institute of Allergy and Infectious… Results Nov 2019 16.6% serious AE View details

Phase 3 N=415 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

Depressive Disorder, Major

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study — -4.1; -5.1 Score on a Scale — p=0.2398

Naurex, Inc, an affiliate of Allergan plc Results Nov 2019 0.7% serious AE View details

Phase 3 N=355 Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

Anaemia

Primary: Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants — 11.97; 11.86 Grams per deciliter (g/dL) — p=<.0001

GlaxoSmithKline Results Nov 2019 29.0% serious AE View details

Phase 3 N=1,021 A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

Primary: Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat…

Hoffmann-La Roche Results Nov 2019 41.5% serious AE View details

Phase 3 N=44 Airway Effects of Tiotropium in Patients With COPD

COPD · LUNG DISEASES, OBSTRUCTIVE

Primary: Peripheral Airways Resistance (R5-R20) — 0.23; 0.2; 0.16 kPa/l/s

Imperial College London Results Nov 2019 0.0% serious AE View details

Phase 3 N=10 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1) — 9 Participants

Janssen Research & Development, LLC Results Nov 2019 30.0% serious AE View details

Phase 3 N=64 Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Thromboembolism of Vein VTE in Colorectal Cancer · Thromboembolism of Vein in Pancreatic Cancer · Thromboembolism of Vein in Non-small Cell Lung Cancer

Primary: Percent Change in D-dimer Value — 9.9; -21.9 percent change — p=0.92

Jeffrey Zwicker, MD Results Nov 2019 0.0% serious AE View details

Phase 3 N=861 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Renal Cell Carcinoma

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review…

Merck Sharp & Dohme LLC Results Nov 2019 35.8% serious AE View details

Phase 3 N=711 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c (Week 26) — -1.2; -1.1; -0.1; -1.4 Percentage of HbA1c — p=<0.0001

Novo Nordisk A/S Results Nov 2019 9.6% serious AE View details

Phase 3 N=731 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c (Week 26) — -0.5; -1.0; -1.3; -0.1 Percentage of HbA1c — p=< 0.0001

Novo Nordisk A/S Results Nov 2019 10.0% serious AE View details

Phase 3 N=4,125 Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

Primary: Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death — 2125; 515; 16 Participants

Novartis Pharmaceuticals Results Nov 2019 12.6% serious AE View details